Effects of newly introduced antidiabetic drugs on autophagy

M. Ashrafizadeh, H. Yaribeygi, Stephen Atkin, Amirhossein Sahebkar

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process.

Original languageEnglish
Pages (from-to)2445-2449
Number of pages5
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Volume13
Issue number4
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Autophagy
Hypoglycemic Agents
Diabetes Mellitus
Proximal Kidney Tubule
Hypoglycemia
Organelles
Cell Survival
Homeostasis
Therapeutics
Pharmacology
Incidence
Glucagon-Like Peptide-1 Receptor

Keywords

  • Autophagy
  • Diabetes mellitus
  • DPP-4
  • GRP-1
  • SGLT

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of newly introduced antidiabetic drugs on autophagy. / Ashrafizadeh, M.; Yaribeygi, H.; Atkin, Stephen; Sahebkar, Amirhossein.

In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 13, No. 4, 01.07.2019, p. 2445-2449.

Research output: Contribution to journalReview article

Ashrafizadeh, M. ; Yaribeygi, H. ; Atkin, Stephen ; Sahebkar, Amirhossein. / Effects of newly introduced antidiabetic drugs on autophagy. In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2019 ; Vol. 13, No. 4. pp. 2445-2449.
@article{2ec6a00399ab4465b91a31168460b455,
title = "Effects of newly introduced antidiabetic drugs on autophagy",
abstract = "Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process.",
keywords = "Autophagy, Diabetes mellitus, DPP-4, GRP-1, SGLT",
author = "M. Ashrafizadeh and H. Yaribeygi and Stephen Atkin and Amirhossein Sahebkar",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.dsx.2019.06.028",
language = "English",
volume = "13",
pages = "2445--2449",
journal = "Diabetes and Metabolic Syndrome: Clinical Research and Reviews",
issn = "1871-4021",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Effects of newly introduced antidiabetic drugs on autophagy

AU - Ashrafizadeh, M.

AU - Yaribeygi, H.

AU - Atkin, Stephen

AU - Sahebkar, Amirhossein

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process.

AB - Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process.

KW - Autophagy

KW - Diabetes mellitus

KW - DPP-4

KW - GRP-1

KW - SGLT

UR - http://www.scopus.com/inward/record.url?scp=85068239910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068239910&partnerID=8YFLogxK

U2 - 10.1016/j.dsx.2019.06.028

DO - 10.1016/j.dsx.2019.06.028

M3 - Review article

VL - 13

SP - 2445

EP - 2449

JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

SN - 1871-4021

IS - 4

ER -